secwatch.observer — SEC 8-K summary
======================================

Issuer:     Camp4 Therapeutics Corp (CAMP)
CIK:        0001736730
Form:       8-K
Filed at:   2026-08-13T20:22:35+00:00
Accession:  0001628280-26-056758
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CAMP4 Q2 net loss $33.5M; CMP-002 trial cleared in Australia/Argentina; $50.1M raised
--------------------------------------------------------------------------------

- Net loss $33.5M vs $12.6M YoY; includes $20.9M non-cash loss on derivative tranche liability.
- Cash $86.4M at June 30, 2026; plus $50.1M from second closing extends runway to end 2028.
- Regulatory clearance from TGA/HREC (Australia) and ANMAT (Argentina) for Phase 1/2 CMP-002 trial; initiation expected Q4 2026.
- R&D expenses $10.8M vs $10.3M; G&A $4.3M vs $4.2M.
- HQ relocated to Watertown, Mass.; Analyst Day Sept 28, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1736730/000162828026056758/0001628280-26-056758-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1736730/000162828026056758/camp-20260813.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-056758

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer